The Significance of Inhibrx Biosciences’ Positive Topline Results of Ozekibart (INBRX-109) in Chondrosarcoma, with Expansion Updates in Colorectal Cancer and Ewing Sarcoma

Introduction

Chondrosarcoma is the second most common primary malignant bone tumor in adults, notorious for its resistance to chemotherapy and radiotherapy, with surgical resection being the mainstay for localized disease. However, for unresectable, locally advanced, or metastatic chondrosarcoma, the prognosis remains dismal, largely due to the absence of effective systemic therapies (van Maldegem et al., 2019).

INBRX-109 (Ozekibart) is a third-generation, recombinant, humanized agonist antibody targeting Death Receptor 5 (DR5, also known as TRAIL-R2), a member of the TNF receptor family that induces apoptotic signaling in tumor cells. The recent positive topline results from its registrational trial in chondrosarcoma, along with updates in colorectal cancer and Ewing sarcoma cohorts, bears substantial clinical implications for patients.

Mechanistic Rationale: Targeting DR5 in Cancer

The Unmet Need

Chondrosarcoma's refractory nature to traditional cytotoxic agents has resulted in 5-year overall survival (OS) rates for unresectable or metastatic disease of less than 10% (Monga et al., 2020). Thus, new molecularly targeted approaches are urgently required.

How INBRX-109 Works

  • DR5 as a Target: DR5 is overexpressed in various tumors, including chondrosarcoma. Activation of DR5 results in apoptotic cell death, making it an attractive therapeutic target (Subbiah et al., 2023).
  • Advanced Antibody Engineering: INBRX-109's tetravalent (four binding sites) configuration enables potent receptor clustering and apoptosis induction, far exceeding the activity of bivalent or trivalent (TRAIL-based) molecules as demonstrated in preclinical models, with a notable improvement in cytotoxic potency (Subbiah et al., 2023).

Preclinical Validation

  • In Vitro Results: INBRX-109 induced dose-dependent apoptosis in chondrosarcoma cells, with superior EC50 values compared to prior attempts at DR5-targeting agents (precise EC50 values in the low nanomolar range).
  • In Vivo Efficacy: In patient-derived xenograft models, INBRX-109 treatment (1 mg/kg weekly for 3 weeks) led to substantial and durable tumor regression compared to vehicle, indicating translational potential (Subbiah et al., 2023).

Phase I Clinical Results in Chondrosarcoma

Patient Population and Methodology

  • Population: Advanced/metastatic conventional chondrosarcoma patients, with no further standard options.
  • Dosing: The majority (except one) received 3 mg/kg INBRX-109, administered intravenously.
  • Evaluable cohort: 31 patients were included in the analysis of efficacy.

Efficacy Outcomes

  • Tumor Response: Among the evaluable patients, a proportion achieved partial response (PR) or stable disease (SD). The clinical benefit (disease control = PR + SD) for greater than 6 months was documented in a significant subset (Subbiah et al., 2023).
  • Durable Disease Control: Notably, durable disease control (defined as SD, PR, or CR >6 months) was achieved in several patients, a remarkable improvement over historical data, where progression is the rule.
  • Progression-Free Survival (PFS): The median PFS reached in this cohort stands in contrast to standard progression rates in this disease, where historical PFS with best supportive care or off-label interventions is approximately 2-3 months (van Maldegem et al., 2019).
  • Growth Modulation Index (GMI): The mean modified GMI (the ratio of PFS on INBRX-109 to prior treatment duration) was above 1 in a relevant number of patients. This index is recognized as a useful surrogate for treatment benefit in rare tumors: values above 1.33 are considered strongly supportive of clinical activity. Several patients in the study achieved a modified GMI crossing this threshold (Subbiah et al., 2023).

Radiographic Evidence

  • Tumor Shrinkage: Representative patients demonstrated PRs with notable reductions in target lesion diameter, as observed by contrast-enhanced CT, and long-lasting SD even in grade 3, metastatic chondrosarcoma.

Safety and Tolerability

  • Hepatotoxicity: INBRX-109’s next-generation engineering aimed to minimize off-target toxicity. Hepatic safety was rigorously tested in preclinical human-liver models and monitored clinically, showing low incidence of liver enzyme elevations, further affirming manageability (Subbiah et al., 2023).
  • Immunogenicity: Preexisting anti-drug antibodies (ADA) were rare, and those detected did not appear to significantly impact clinical safety—an improvement over prior agents in this class.
  • General AEs: No drug-related deaths. Toxicity profile was acceptable, with the majority of adverse events being low grade, and manageable with supportive measures.

Expanding the Scope: Colorectal Cancer and Ewing Sarcoma

Although detailed topline results from the colorectal cancer and Ewing sarcoma cohorts are not included in this selection, the ongoing expansion into these solid tumor types highlights INBRX-109’s multi-indication potential, aiming to address similarly high unmet needs in other aggressive cancers.

Broader Impact: Raising the Standard of Care

For Patients with Chondrosarcoma

  1. First Active Systemic Option: For decades, systemic therapy for chondrosarcoma has been ineffective. The durable disease control and meaningful PFS reported with INBRX-109 may shift the treatment paradigm and offer non-surgical patients genuine hope for disease stability and extended survival (Subbiah et al., 2023).
  2. Quality of Life: By reducing symptom burden due to uncontrolled tumor growth, patients may experience better function, pain control, and less need for aggressive interventions.
  3. Safety: A tolerable safety profile increases the accessibility of the drug to frail or comorbid individuals otherwise excluded from cytotoxic regimens.

For the Sarcoma Community and Oncology at Large

  • Proof-of-Concept for DR5 Agonism: The success of INBRX-109 in chondrosarcoma could spur the development of DR5-targeted agents in other cancers.
  • Personalized Oncology: As a monoclonal antibody, INBRX-109 may benefit from biomarker-driven patient selection strategies moving forward.

Conclusion

The positive topline results for INBRX-109 (Ozekibart) in chondrosarcoma signify a watershed moment for patients with this devastating disease. For the first time, a targeted therapy demonstrates robust, durable disease control in a population with little or no therapeutic recourse. The manageable safety profile further underlines its relevance.

If corroborated by subsequent trial phases and regulatory approval, INBRX-109 is poised to become the first approved systemic therapy for advanced chondrosarcoma, improving both survival and quality of life for patients. Expansion into colorectal cancer and Ewing sarcoma, if successful, could enlarge its impact across oncology.

References

  • (Subbiah et al., 2023): Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clinical Cancer Research, 2023 Aug 15;29(16):2988-3003. doi:10.1158/1078-0432.CCR-23-0974
  • (van Maldegem et al., 2019): Outcome of first-line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma. Oncologist 2019;24:110–6.
  • (Monga et al., 2020): Non-conventional treatments for conventional chondrosarcoma. Cancers (Basel) 2020;12:1962.

In summary: For patients, these results represent not just an incremental advance, but potentially the first major breakthrough in the systemic treatment of advanced chondrosarcoma, and possibly a platform for further advances in other hard-to-treat malignancies.